{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:09Z","timestamp":1792184649128,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T00:00:00Z","timestamp":1032220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors (SSRIs) have been used more frequently. In the present study, the efficacy and side\u2010effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM\u2010III\u2010R were randomly assigned to two subgroups; citalopram (<jats:italic>n<\/jats:italic>\u2009=\u200936) or moclobemide (<jats:italic>n<\/jats:italic>\u2009=\u200935). The study was an 8\u2010week, randomized, open\u2010label, rater\u2010blinded, parallel\u2010group trial. All patients were assessed by Hamilton anxiety rating (HAM\u2010A), Liebowitz social anxiety (LSAS), clinical global impression\u2010severity of illness (CGI\u2010SI) and clinical global impression\u2010improvement (CGI\u2010I) scales. There was a similar percentage of responders (citalopram 75%, <jats:italic>n<\/jats:italic>\u2009=\u200927 and moclobemide 74.3%, <jats:italic>n<\/jats:italic>\u2009=\u200926), with a &gt;50% or greater reduction in LSAS total score and ratings of \u2018very much\u2019 or \u2018much improved\u2019 on the CGI\u2010I. None of the patients withdrew from the study. The results of the present study suggest that citalopram has shown promising results in patients with SP. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.436","type":"journal-article","created":{"date-parts":[[2002,12,2]],"date-time":"2002-12-02T13:47:08Z","timestamp":1038836828000},"page":"401-405","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings"],"prefix":"10.1002","volume":"17","author":[{"given":"Murad","family":"Atmaca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kuloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertan","family":"Tezcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1990.01810140091015"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.2.120"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014162"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00182-1"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199108000-00023"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1995.tb09596.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_9_1","first-page":"74","article-title":"Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies","volume":"30","author":"Juster HT","year":"1996","journal-title":"Prog Behav Modif"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1996)4:3<100::AID-DA2>3.0.CO;2-K"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.9.1368"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.5.613"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014302"},{"key":"e_1_2_1_14_1","volume-title":"Modern Problems of Pharmacopsychiatry","author":"Liebowitz MR","year":"1987"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.290"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00003"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.123.2.218"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00002"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb14580.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200104000-00020"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199202000-00018"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.1.70"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00189-0"},{"key":"e_1_2_1_24_1","volume-title":"Structured Interview for DSM\u2010III\u2010R, Patient Edition\/Non\u2010patient Edition (SCID\u2010P\/SCID\u2010NP)","author":"Spitzer RL","year":"1990"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199606000-00005"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.5.756"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.8.708"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02900196"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/080394899427656"},{"key":"e_1_2_1_30_1","first-page":"27","article-title":"Fluoxetine efficacy in social phobia","volume":"54","author":"Van Ameringen M","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(99)00109-8"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244762"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199709000-00001"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.3.353"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00014"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.168.2.169"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.436","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:11:12Z","timestamp":1700395872000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,17]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1002\/hup.436"],"URL":"https:\/\/doi.org\/10.1002\/hup.436","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,17]]}}}